GlassScriptPhysician profile
Shivaprasad Marulendra
NPI 1205810926
$2,593.08
in general payments reported to CMS, 2019-2025
21 companies · $373 in 2025
The $373 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $429 · 2021: $201 · 2022: $46.47 · 2023: $163 · 2024: $843 · 2025: $373.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,379.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $844.14 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.15 | 2019-2020 | |
| Janssen Biotech, INC. | $251.72 | 2024-2025 | Tremfya, Stelara, Simponi |
| Phathom Pharmaceuticals, INC. | $199.07 | 2024-2025 | Voquezna |
| Braintree Laboratories, INC. | $151.84 | 2019-2025 | Suflave, Sutab |
| Ipsen Biopharmaceuticals, INC | $150.00 | 2024 | Iqirvo |
| Boston Scientific Corporation | $121.61 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $115.80 | 2019-2025 | Entyvio |
| Pfizer INC. | $96.18 | 2024-2025 | |
| Madrigal Pharmaceuticals | $68.73 | 2024-2025 | Rezdiffra, Resmetirom |
| Daiichi Sankyo INC. | $54.05 | 2023-2024 | Injectafer |
| Celltrion USA INC. | $51.93 | 2024-2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $49.52 | 2021-2022 | |
| Ironwood Pharmaceuticals, INC | $30.39 | 2020 | |
| Allergan, INC. | $23.74 | 2019 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $20.92 | 2024 | Endoflip |
| Alfasigma USA, INC. | $20.59 | 2020 | |
| Genzyme Corporation | $20.06 | 2025 | |
| Ardelyx, INC. | $18.04 | 2024 | Ibsrela |
| Lilly USA, LLC | $17.41 | 2025 | Omvoh |
| Celgene Corporation | $14.19 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shivaprasad Marulendra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.